CRP and premenstrual tension: According to the indications for therapy, a significant reduction in PMS was obtained in the first-line therapy group with respect to the others from baseline to the two-month follow-up, while a non-significant difference was observed when considering either C-reactive protein or fecal calprotectin variation (Figure 4A–C).